
NASDAQ: CRGX

CARGO THERAPEUTICS

ENGINEERING NEXT GENERATION CAR T-CELL THERAPIES TO DELIVER MORE CURES

J.P. MORGAN HEALTHCARE CONFERENCE 2024



FORWARD-LOOKING STATEMENTS/Disclaimers

- This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may include the words "believe", "expect", "anticipate", "intend", "plan", "estimate", "project", "will", "may", "targeting" and similar expressions as well as statements other than statements of historical facts including, without limitation, those regarding business strategy, plans, estimated milestones and objectives of the management of the Company. Such forward-looking statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks, including business, regulatory, econo and competitive risks, uncertainties, contingencies and assumptions about the Company, including, without limitation, risks inherent in developing CRG-022 or CRG-023, future results from the Company's ongoing and planned clinical trials, the Company's ability to obtain adequate financing to fund its planned clinical trials and other expenses, trends in the industry, the legal and regulatory framework for the industry and future expenditures. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The actual results may vary from the anticipated results and the variations may be material. These forward-looking statements should not be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such forward-looking statements have been made are correct or exhaustive or, in the case of the assumptions, fully stated in the presentation. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this presentation is given. These and other risks are described more fully in CARGO's filings with the Securities and Exchange Commission (SEC) including its Registration Statement on Form S-1 filed with the SEC on October 10, 2023 (and as subsequently amended) or in other documents CARGO subsequently files with or furnishes to the SEC. CARGO undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events or changes in its expectations.
- Information in this presentation (including market data and statistical information) has been obtained from various sources (including third-party sources) and the Company does not guarantee the accuracy or completeness of such information. All projections, valuations and statistical analyses are provided for information purposes only. They may be based on subjective assessments and assumptions and may use one among many alternative methodologies that produce different results and to the extent they are based on historical information, they should not be relied upon as an accurate prediction of future performance, and you are cautioned not to give undue weight to them.
- This presentation discusses product candidates that are under clinical study and which have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of these product candidates for the therapeutic use for which such product candidates are being studied.
- The Phase 1 clinical trial for CRG-022 referenced herein was conducted by Stanford using their formulation of CRG-022. The Company has made additional process and analytical improvements to the Stanford process to create the intended commercial manufacturing process for CRG-022 in an effort to improve manufacturing yields and efficiency.



CARGO – developing potentially curative cell therapies

Transformative and growing CAR T market	 Autologous CART revenue in DLBCL is estimated to reach \$3.3B by 2030 Patient access is broadening as more treatment centers offer CART
Significant unmet need post CD19 CAR T	 CRG-022 may address the ~60% of LBCL patients who do not achieve a durable resp therapy⁽¹⁾ By 2030, ~7,600 patients expected to need treatment post CD19 CART-cell therapy in
CRG-022: targeting CD22, potentially pivotal stage	 Positive Phase 1 results in CD19 CART R/R LBCL – 53% CR rate with impressive durabile 120+ patients dosed across multiple clinical trials and CRG-022 was generally well-tole Initiated potentially pivotal Phase 2 clinical trial; multiple patients dosed with success leveraging our intended commercial and readily transferable manufacturing process Stanford was granted Breakthrough Therapy Designation by FDA
Platform technologies and tri-specific program	 Leveraging proprietary cell engineering platform technologies to develop a pipeline multiple transgene therapeutic "cargo" designed to address mechanisms of resistance CRG-023, an IND-enabling stage tri-specific targeting CD19, CD20 and CD22, incorport integrates a novel CD2 costimulatory domain to counter downregulation of CD58
World class team and well capitalized	 Co-founded in 2021 by globally recognized pioneers and leaders in oncology and cell Seasoned, strong leadership team with deep cell therapy and oncology experience November 2023 IPO raised approximately \$320M gross proceeds, NASDAQ ticker: CR

Source: Yi-Jiun Su, et al. ASH 2023, Nov'2023 data cutoff

Source: Five-year follow-up of ZUMA-1 trial; 1) N Engl J. Med 2017;377:2531-44 DOI: 10.1056/NEJMoa1707447; 2) Clarivate Disease and Landscape Forecasting (NHL, CLL) 2023; US/EU4/UK and CARGO company analysis



oonse with CD19 CAR T-cell

n US/EU4/UK alone⁽²⁾

lity and safety

erated

essful manufacturing to date,

of programs that incorporate

rates first platform, which

l therapy

GX

Pipeline of transformative CAR T-cell therapies to deliver cures addressing mechanisms of resistance

Resistance mechanism	Solutions
Antigen escape (e.g., CD19)	Target Alt Antigen or Multi-specific CAR designs
Loss of costimulation (e.g., CD58)	CAR-Engineered, CD2 technology
Immune rejection of product	Human binders
Tumor burden, loss of functional persistence	Design, lead selection and MFG

Potentially pivotal Phase 2 topline data for lead product candidate CRG-022 expected in 2025

				Stage	e of Develop	oment			
Program	Target(s)	Indication(s)	Discovery	IND- enabling	Phase 1	Phase 2	Phase 3	Commerc rights	
CRG-022 (CART)	CD22	R/R LBCL - post CD19 CAR T						~ ~ ~ ~	
		LBCL - CART naïve ⁽¹⁾						THERAPEUTI	
		Pediatric B-ALL							
CRG-023 (tri-specific CART with CD2 co- stimulation)	CD19 CD20 CD22	B-cell malignancies						CARG	

(1) Based on data from the Phase 1 clinical trial conducted by Stanford and our ongoing Phase 2 clinical trial in R/R LBCL - post CD19 CAR T, we intend to discuss with the FDA initiation of a Phase 2 program in LBCL- CAR T naïve without completing earlier clinical trials in LBCL - CART naïve patients












CD19 CAR T-cell therapy: transformative and growing



Source: Clarivate Disease and Landscape Forecasting (NHL, CLL) 2022; US/EU4/UK



 Autologous CD19 CAR T-cell therapies to potentially become Standard of Care for relapsed / refractory Large B-Cell Lymphoma


(R/R LBCL)

addressed

 Recent approvals in earlier lines of therapy and additional geographies anticipated to continue to fuel growth

 Patient access broadening as more treatment centers offer CAR T and manufacturing challenges are

CRG-022 could address a significant and growing unmet need for patients whose disease is R/R to CD19 CAR T-cell therapy



Source: Five-year follow-up of ZUMA-1 trial; 1) N Engl J. Med 2017;377:2531-44 DOI: 10.1056/NEJMoa1707447; (2) Clarivate Disease and Landscape Forecasting (NHL, CLL) 2023; US/EU4/UK and CARGO company analysis



• ~60% of LBCL patients were observed to not achieve a durable response with CD19 CAR T-cell therapy⁽¹⁾

 High unmet need with no standard of care for post CD19 CAR T patients and poor


• By 2030, approximately 7,600 patients expected to need treatment post CD19 CAR T-cell therapy in US/EU4/UK alone⁽²⁾







Phase 1 design: Stanford study of CRG-022 CAR T in R/R LBCL



Abbreviations: **CAR19** = anti-CD19 CAR T-cell therapy; **R/R** = relapsed or refractory; **CRC-022** = anti-CD22 CAR T-cell therapy; **DL** = dose level; **RP2D** = recommended phase 2 dose; **TEAE** = treatment-emergent adverse events; **ORR** = overall response rate; **DOR** = duration of response; **PFS** = progression free survival; **OS** = overall survival; **ULN** = upper limit of normal; Note: Response was classified according to Lugano criteria for LBCL Source: Cheson BD, et al. J Clin Oncol. 2014; 32(27):3059-67; Lee DW, et al. Biol Blood Marrow Transplant. 2019; 25(4):625-38; Frank MJ et al. EHA 2023

CARGO THERAPEUTICS

Baseline Characteristics of Treated Patients

(N=38)

- 97% progressed after prior CD19 CAR T
- Median age 65 years old
- Median 4 prior lines of therapy
- 76% had DLBCL; 16% doublehit status
- 84% had elevated lactate dehydrogenase (high tumor burden)


Primary Endpoints

- Safety and toxicity (TEAEs)
- Recommended Phase 2 dose
- Manufacturing feasibility

Key Secondary Endpoints

- ORR* (investigator-assessed)
- DOR/PFS/OS
- Pharmacokinetics

Phase 1 results: CRG-022 demonstrated potential to be an effective therapy for LBCL patients whose disease is R/R to CD19 CAR T-cell therapy



Source: Stanford Phase 1 data presentation at ASH Investigator meeting; Yi-Jiun Su, et al. ASH 2023; Nov'2023 data cutoff Five patients who died of non-relapse causes were in CR at the time of death; 2 of 5 patients were in Dose Level 1 and 3 of 5 patients were in Dose Level 2. 1) 2 patients relapsed. 3 patients died (1 related, 2 unrelated): NR: Not reached



Key Takeaways

- CR rate: **53%**
- ORR rate: 68%
- CRs typically durable with only 4 of 20 pts who achieved a CR have relapsed
- Manufacturing success rate: 95%
 Dose Level 1

 1 million CAR+ cells/kg

 Dose Level 2

 3 million CAR+ cells/kg

Phase 1 results: CRG-022 was generally well-tolerated

Parameter	DLBCL DL1 (n=29)	DLBCL DL2 (n=9)	Total n=38		Grade 3+ rates			
Cytokine Release Syndrome, n (%)				A	pproved Cl	D19 CAR T-c	ell therapies ⁽³⁾	
None	2 (7%)	0 (0%)	2 (5%)					
Grade 1	13 (45%)	1 (11%)	14 (37%)		ZUMA-1 (axi-cel)	JULIET (tisagen)	TRANSCEND (liso-cel)	
Grade 2	14 (48%)	7 (78%)	21 (55%)					
Grade≥3	0 (0%)	1 (11%)	1 (3%)		13%	22%	2%	
Neurologic Events / ICANS, n (%)								
None	26 (90%)	7 (78%)	33 (87%)					
Grade 1	2 (7%)	1 (11%)	3 (8%)					
Grade 2	1 (3%)	1 (11%)	2 (5%)					
Grade≥3	0 (0%)	0 (0%)	0 (0%)		28%	12%	10%	

Abbreviations: **IEC-HS** = Immune effector cell HLH-like syndrome; **carHLH** = Chimeric Antigen Receptor T-Cell-Associated Hemophagocytic Lymphohistiocytosis Source: ⁽¹⁾ Hines et al. 2021; ⁽²⁾ Ahmed et al. 2020; ⁽³⁾ Data reported from clinical studies for each approved therapy and not from head-to-head studies with CRG-022. Source: Stanford Phase 1 data analysis shared at ASH 2023 Investigator meeting



IEC-HS incidence

- DL1: 7%
- DL2:33%
- Total: 18%


Managed with anakinra and steroids

Real world incidence of carHLH with CD19 CARs:

• Peds B-ALL: 14.8%

• DLBCL: 6%

Potentially pivotal Phase 2 clinical trial of CRG-022 in R/R LBCL Currently enrolling



Abbreviations: LBCL = large B-cell lymphoma; R/R = relapsed or refractory; PET/CT = positron emission tomography/ computed tomography; ORR = overall response rate;






Endpoint

Primary endpoint


• ORR per PET/CT

CRG-022: Differentiated CAR-mediated activity and commercially suitable manufacturing process

Design: Chimeric antigen receptor (CAR) has differentiated functional potential



Manufacturing: Address Commercial Suitability While Maintaining Product Comparability








Pipeline & platform overview





CARGO's pipeline: CRG-023, Tri-Specific CAR T targeting CD19, CD20, CD22




3 distinct CARs. Each with unique co-stimulatory domains, including 1 CAR with novel CD2 co-stim

Expressed from 1 vector

New Hu scFv binders for CD19, 20.

1000s of constructs screened

Seasoned leadership team with significant oncology and cell therapy experience







CARGO – focused on developing and delivering potentially curative cell therapies

Key takeaways

- Impressive Phase I results of CRG-022 in CD19 CAR T R/R LBCL
- Currently enrolling potentially pivotal Phase 2 clinical trial, with topline data expected in 2025
- Developed strong commercial and readily transferable manufacturing process for all clinical trials
- Leveraging proprietary cell engineering platform technologies to develop a pipeline of programs
- Seasoned, strong leadership team
- Total cash at hand (as of 31 Dec 2023): \$406M

Strong financial position and significant value inflection points November 2023 following IPO August 2023 in LBCL R/R CD19 2025 (expected) CRG-022 in LBCL R/R CD19

- Raised **\$320M in gross proceeds**
- Initiation of Phase 2 for CRG-022
- Interim Phase 2 results for

*Includes Series A Tranche 3 Note: As of May 3, 2023 data cutoff date



Thank you

